Shenep J L, Hughes W T, Flynn P M, Roberson P K, Behm F G, Fullen G H, Kovnar S G, Guito K P, Brodkey T O
Department of Infectious Diseases, St. Jude Children's Research Hospital, Memphis, Tennessee 38105.
Antimicrob Agents Chemother. 1994 Jul;38(7):1644-6. doi: 10.1128/AAC.38.7.1644.
Nineteen young human immunodeficiency virus-infected patients were randomized to receive 400 mg of oral diethyldithiocarbamate (DTC) per m2 or placebo weekly for 12 weeks. Changes in blood CD4+ lymphocytes were not significantly different between groups. However, neutrophil, monocyte, and platelet counts consistently decreased during DTC treatment, suggesting DTC-mediated myelosuppression.
19名年轻的人类免疫缺陷病毒感染患者被随机分组,分别接受每平方米400毫克口服二乙二硫代氨基甲酸盐(DTC)或安慰剂治疗,每周一次,共12周。两组之间血液CD4 +淋巴细胞的变化无显著差异。然而,在DTC治疗期间,中性粒细胞、单核细胞和血小板计数持续下降,提示DTC介导的骨髓抑制。